Technical Analysis for BGNE - BeiGene, Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 172.85 | 1.06% | 1.82 |
Earnings due: Jun 5
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 1.06% | |
| Multiple of Ten Bullish | Other | 1.06% | |
| Gapped Up | Strength | 1.06% | |
| 180 Bullish Setup | Bullish Swing Setup | 4.83% |
| Alert | Time |
|---|---|
| 200 DMA Resistance | 1 day ago |
| Possible Pocket Pivot | 1 day ago |
| 1.5x Volume Pace | 1 day ago |
| Up 2% | 1 day ago |
| Rose Above 200 DMA | 1 day ago |
Get a Trading Assistant
- Earnings date: 06/05/2024
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Monoclonal Antibodies Monoclonal Antibody Lymphoma Oncogenes Protein Kinase Bruton's Tyrosine Kinase Ras Subfamily Rp1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 245.74 |
| 52 Week Low | 126.9681 |
| Average Volume | 197,522 |
| 200-Day Moving Average | 173.39 |
| 50-Day Moving Average | 155.41 |
| 20-Day Moving Average | 157.82 |
| 10-Day Moving Average | 164.90 |
| Average True Range | 5.71 |
| RSI (14) | 66.78 |
| ADX | 23.5 |
| +DI | 36.81 |
| -DI | 17.40 |
| Chandelier Exit (Long, 3 ATRs) | 158.87 |
| Chandelier Exit (Short, 3 ATRs) | 144.10 |
| Upper Bollinger Bands | 178.33 |
| Lower Bollinger Band | 137.31 |
| Percent B (%b) | 0.87 |
| BandWidth | 25.99 |
| MACD Line | 5.05 |
| MACD Signal Line | 3.52 |
| MACD Histogram | 1.5307 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 182.21 | ||||
| Resistance 3 (R3) | 182.22 | 179.11 | 180.65 | ||
| Resistance 2 (R2) | 179.11 | 176.73 | 179.11 | 180.13 | |
| Resistance 1 (R1) | 175.98 | 175.25 | 177.55 | 175.97 | 179.61 |
| Pivot Point | 172.87 | 172.87 | 173.65 | 172.87 | 172.87 |
| Support 1 (S1) | 169.74 | 170.49 | 171.31 | 169.73 | 166.09 |
| Support 2 (S2) | 166.63 | 169.01 | 166.63 | 165.57 | |
| Support 3 (S3) | 163.50 | 166.63 | 165.05 | ||
| Support 4 (S4) | 163.49 |
